Kaser D.J.,Reproductive Medicine Associates of New Jersey |
Kaser D.J.,Thomas Jefferson University
Journal of Assisted Reproduction and Genetics | Year: 2017
Fellows in Reproductive Endocrinology and Infertility training are expected to complete 18 months of clinical, basic, or epidemiological research. The goal of this research is not only to provide the basis for the thesis section of the oral board exam but also to spark interest in reproductive medicine research and to provide the next generation of physician-scientists with a foundational experience in research design and implementation. Incoming fellows often have varying degrees of training in research methodology and, likewise, different career goals. Ideally, selection of a thesis topic and mentor should be geared toward defining an “answerable” question and building a practical skill set for future investigation. This contribution to the JARG Young Investigator’s Forum revisits the steps of the scientific method through the lens of one recently graduated fellow and his project aimed to test the hypothesis that “sequential oxygen exposure (5% from days 1 to 3, then 2% from days 3 to 5) improves blastocyst yield and quality compared to continuous exposure to 5% oxygen among human preimplantation embryos.” © 2017 Springer Science+Business Media New York
Morin S.J.,Reproductive Medicine Associates of New Jersey |
Morin S.J.,Thomas Jefferson University
Journal of Assisted Reproduction and Genetics | Year: 2017
There has been much debate regarding the optimal oxygen tension in clinical embryo culture. The majority of the literature to date has compared 5% oxygen to atmospheric levels (20–21%). While the majority of modern IVF labs have accepted the superiority of 5% oxygen tension, a new debate has emerged regarding whether a further reduction after day 3 of development represents the most physiologic system. This new avenue of research is based on the premise that oxygen tension is in fact lower in the uterus than in the oviduct and that the embryo crosses the uterotubal junction sometime on day 3. While data are currently limited, recent experience with ultra-low oxygen (2%) after day 3 of development suggests that the optimal oxygen tension in embryo culture may depend on the stage of development. This review article will consider the current state of the literature and discuss ongoing efforts at studying ultra-low oxygen tension in extended culture. © 2017 Springer Science+Business Media New York
News Article | April 18, 2017
— Infertility is the failure to achieve pregnancy after 12 months of unprotected intercourse. Infertility occurs due to the abnormal functioning of the female and male reproductive system. It can be treated with infertility drugs and through procedures such as artificial insemination, in-vitro fertilization, and surrogacy. Read more details of the report at Orbis Research The report covers the present scenario and the growth prospects of the infertility services market in US for 2017-2021. To calculate the market size, the report considers the services carried out during treatment via infertility drugs and assisted reproductive technology (ART) services. Research report, Infertility Services Market in US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Request sample copy of the report at: http://www.orbisresearch.com/contacts/request-sample/244699 Other prominent vendors • AbbVie • Apricus Biosciences • AstraZeneca • Auxogyn • Eli Lilly • EMD Serono • IKS International • InVitro Care • INVO Bioscience • Irvine Scientific • LifeGlobal • MedITEX • NMC Health • OB GYN Associates • OvaScience • Pantec Biosolutions • Reproductive Medicine Associates of New Jersey • The Sims Clinic • TriHealth • Virtus Health • Xytex Cryo International Market driver • Rising success rate of infertility treatments. • For a full, detailed list, view our report Market challenge • Limited reimbursements and lack of strict regulatory oversight. • For a full, detailed list, view our report Market trend • Upsurge in mergers and acquisitions. • For a full, detailed list, view our report Key questions answered in this report • What will the market size be in 2021 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. CARE facility, CooperSurgical, Ferring Pharmaceuticals, Monash IVF, Merck, Vitrolife, AbbVie, Apricus Biosciences, AstraZeneca, Auxogyn, Eli Lilly, EMD Serono, IKS International, InVitro Care, INVO Bioscience, Irvine Scientific, LifeGlobal, MedITEX, NMC Health, OB GYN Associates, OvaScience, Pantec Biosolutions, Reproductive Medicine Associates of New Jersey, The Sims Clinic, TriHealth, Virtus Health, Xytex Cryo International. Enquire more details of the report at: http://www.orbisresearch.com/contact/purchase/244699 About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/infertility-services-market-in-us-2017-2021
News Article | May 4, 2017
"RMANJ has focused on innovation and a comprehensive, evidence-based approach for our standard of care for patients," said Dr. Thomas Molinaro, a partner at RMANJ and leading reproductive endocrinologist at the Eatontown, NJ office. "While high success rates are important, so are healthy pregnancies and safe deliveries. At RMANJ, we've been able to maintain high delivery rates while performing single embryo transfers for most patients. Transferring multiple embryos may increase success rates but it comes with potential burdens and complications associated with twins and multiples." RMANJ's success rates can be attributed to the quality of its IVF laboratory, as well as its use of breakthrough technologies, such as comprehensive chromosome screening (SelectCCS) – which more accurately detects healthy embryos that will lead to successful pregnancies and healthy deliveries. SelectCCS is a one-of-a-kind process that screens all 24 chromosomes at a molecular level – making it more accurate than previous testing processes that only count a handful of chromosomes. In fact, SelectCCS has demonstrated to be 98% accurate in determining embryos that have an abnormal number of chromosomes (aneuploidy). RMANJ's delivery rates are also impacted by the experience and dedication of its healthcare providers, individualized IVF protocols and techniques like endometrial synchrony, trophectoderm biopsy, extended embryo culture. RMANJ offers the widest range of services including: IVF, SelectCCS, pre-implantation genetic diagnosis (PGD), egg donation, gestational surrogacy, and collaborative wellness care (i.e., acupuncture, yoga, patient-to-patient networking). As required by the Fertility Clinic Success Rate and Certification Act of 1992, reproductive endocrinologists must report IVF delivery rates to the Centers for Disease Control and Prevention (CDC) and SART, the primary organization of professionals dedicated to the practice of assisted reproductive technologies in the United States. You can view the Final 2014 and the Preliminary 2015 SART Clinic Summary Reports at www.sart.org. About Reproductive Medicine Associates of New Jersey Since 1999, the leaders at RMANJ have helped bring more than 40,000 babies to loving families. In addition to serving as the Division of Reproductive Endocrinology at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ (www.reifellowship.com) and the Reproductive Endocrinology and Infertility Fellowship Program for Sidney Kimmel Medical College of Thomas Jefferson University, the practice currently has twenty-five physicians and ten locations in New Jersey: Basking Ridge, Eatontown, Englewood, Freehold, Hamilton, Morristown, Somerset, Springfield, West Orange, and its newest location in Marlton, New Jersey. For more information visit www.rmanj.com. *SART 2014; Final Live Birth per Patient. Live births of 86.6% includes all non-banking autologous cycles and banking cycles with a thaw within 12 months of banking, representing outcomes for patients who were new to a given clinic in 2014, with births realized in 2014 and 2015. A comparison of clinic success rates may not be meaningful because a patient's medical characteristics, treatment approaches and entrance criteria for assisted reproductive technology (ART) may vary from clinic to clinic. Visit www.sart.org to learn more. ABOUT SART Society for Assisted Reproductive Technology (SART) is the primary organization of professionals dedicated to the practice of assisted reproductive technologies (ART) in the United States. ART includes the practice of in vitro fertilization (IVF). The mission of our organization is to set up and help maintain the standards for ART in an effort to better serve our members and our patients. Visit www.sart.org to learn more. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/reproductive-medicine-associates-of-new-jersey-shows-86-delivery-rate-according-to-latest-sart-ivf-report-300451452.html
News Article | November 7, 2016
BASKING RIDGE, N.J., Nov. 7, 2016 /PRNewswire/ -- Reproductive Medicine Associates of New Jersey (RMANJ), a world-renowned leader in the field of infertility, today announced that their Helping Heroes Build Families program would continue into 2017 – its fifth year. Through the program,...
Treff N.R.,Reproductive Medicine Associates of New Jersey |
Treff N.R.,University of New Brunswick |
Treff N.R.,Rutgers University |
Scott Jr. R.T.,Reproductive Medicine Associates of New Jersey |
Scott Jr. R.T.,University of New Brunswick
Fertility and Sterility | Year: 2013
Embryonic comprehensive chromosomal euploidy may represent a powerful biomarker to improve the success of IVF. However, there are a number of aneuploidy screening strategies to consider, including different technologic platforms with which to interrogate the embryonic DNA, and different embryonic developmental stages from which DNA can be analyzed. Although there are advantages and disadvantages associated with each strategy, a series of experiments producing evidence of accuracy, safety, clinical predictive value, and clinical efficacy indicate that trophectoderm biopsy and quantitative real-time polymerase chain reaction (qPCR)-based comprehensive chromosome screening (CCS) may represent a useful strategy to improve the success of IVF. This Biomarkers in Reproductive Medicine special issue review summarizes the accumulated experience with the development and clinical application of a 4-hour blastocyst qPCR-based CCS technology. Copyright © 2013 American Society for Reproductive Medicine, Published by Elsevier Inc.
Treff N.R.,Reproductive Medicine Associates of New Jersey |
Treff N.R.,University of New Brunswick |
Treff N.R.,Rutgers University
Seminars in Reproductive Medicine | Year: 2012
An exciting era in preimplantation genetic diagnosis (PGD) is emerging with the adaptation and development of new high throughput genome-wide methodologies for the evaluation of aneuploidy. In fact, many promising preclinical studies and clinical trials involving comprehensive chromosome screening (CCS) have renewed clinician interest in the use of PGD for aneuploidy screening as an embryo selection tool to improve the success of in vitro fertilization (IVF). This review will provide an overview of the basic underlying features and applications of the growing number of platforms and strategies for preimplantation genome-wide analysis of aneuploidy. Copyright © 2012 by Thieme Medical Publishers, Inc.
News Article | February 16, 2017
VALENCIA, Spain and BASKING RIDGE, N.J., Feb. 16, 2017 /PRNewswire/ -- The management division of Reproductive Medicine Associates of New Jersey (RMANJ) and The Valencian Infertility Institute (IVI) announced they are combining their businesses to create a new company called IVI-RMA...
Forman E.J.,Reproductive Medicine Associates of New Jersey |
Hong K.H.,Reproductive Medicine Associates of New Jersey |
Franasiak J.M.,Reproductive Medicine Associates of New Jersey |
Scott Jr. R.T.,Reproductive Medicine Associates of New Jersey
American Journal of Obstetrics and Gynecology | Year: 2014
Objective We sought to determine whether performing elective single embryo transfer (eSET) after trophectoderm biopsy and rapid aneuploidy screening results in improved obstetrical and neonatal outcomes compared with transferring 2 untested embryos. Study Design The Blastocyst Euploid Selective Transfer (BEST) Trial enrolled infertile couples with a female partner up to age 42 years who were undergoing in vitro fertilization. They were randomized to receive transfer of a single euploid embryo (eSET) or to the standard of care with transfer of 2 embryos that were not biopsied for aneuploidy screening (untested 2-embryo transfer). Gestational age at delivery, birthweight, and neonatal intensive care unit (NICU) lengths of stay were compared with Mann-Whitney U. The risk of preterm delivery, low birthweight, and NICU admission were compared with χ2. Results Among the 175 randomized patients, the delivery rates were similar (69% after euploid eSET vs 72% after untested 2-embryo transfer; P =.6) through the fresh cycle and up to 1 frozen transfer, with a dramatic difference in multiple births (1.6% vs 47%; P <.0001). The risk of preterm delivery (P =.03), low birthweight (P =.002), and NICU admission (P =.04) were significantly higher after untested 2-embryo transfer. Babies born after untested 2-embryo transfer spent >5 times as many days in the NICU (479 vs 93 days; P =.03). Conclusion By enhancing embryo selection with a validated method of aneuploidy screening, a single euploid embryo with high reproductive potential can be selected for transfer. Using this approach, eSET can be performed without compromising delivery rates and improving the chance of having a healthy, term singleton delivery after in vitro fertilization. © 2014 Mosby, Inc. All rights reserved.
Gardner D.K.,University of Melbourne |
Meseguer M.,Laboratorio Fiv |
Rubio C.,Igenomix And Fundacion Instituto Valenciano Of Infertilidad Fivi Incliva |
Treff N.R.,Reproductive Medicine Associates of New Jersey
Human Reproduction Update | Year: 2015
BACKGROUND: Transfer of more than a single embryo in an IVF cycle comes with the finite possibility of a multiple gestation. Even a twin pregnancy confers significant risk to both mother and babies. The move to single-embryo transfer for all patients will be greatly facilitated by the ability to quantify embryo viability. Developments in time-lapse incubation systems have provided new insights into the developmental kinetics of the human preimplantation embryo. Advances in molecular methods of chromosomal analysis have created platforms for highly effective screening of biopsied embryos, while noninvasive analysis of embryo physiology reveals more about the embryo than can be determined by morphology alone. METHODS: Recent developments in time-lapse microscopy, molecular karyotyping and in proteomics and metabolomics have been assessed and presented here in a descriptive review. RESULTS AND CONCLUSIONS: New algorithms are being created for embryo selection based on their developmental kinetics in culture, and the impact of factors such as patient etiology and treatment are being clarified. Potential links between morphokinetic data and embryo karyotype are being elucidated. The introduction of new molecular methods of determining embryo chromosomal complement is proving to be accurate and reproducible, with the future trending toward CGH arrays or next generation sequencing as a rapid and reliable means of analysis, that should be suitable for each IVF clinic to adopt. A relationship between embryo metabolism and viability is established and is now being considered together with morphokinetic data to create more robust algorithms for embryo selection. Microfluidic devices have the capacity and potential to be used in human IVF clinics for the routine diagnosis of embryo biomarkers. © The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.